Otsuka Pharmaceutical
Otsuka Pharmaceutical Co., Ltd., commonly referred to as Otsuka, is a leading global healthcare company headquartered in Japan. Established in 1964, Otsuka has made significant strides in the pharmaceutical and nutraceutical industries, focusing on innovative solutions for mental health, oncology, and general healthcare. With a strong presence in regions such as North America, Europe, and Asia, Otsuka is renowned for its unique products, including the antipsychotic medication Abilify and the hydration solution Pocari Sweat. The company’s commitment to research and development has positioned it as a pioneer in addressing unmet medical needs. Otsuka's dedication to innovation and patient care has earned it a notable reputation in the global market, making it a key player in the pharmaceutical landscape.
DitchCarbon Score
How does Otsuka Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Otsuka Pharmaceutical's score of 60 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Otsuka Pharmaceutical's reported carbon emissions
In 2023, Otsuka Pharmaceutical reported total carbon emissions of approximately 109,739,000 kg CO2e for Scope 1 and about 13,950,000 kg CO2e for Scope 2 on a global scale. In Japan, the company recorded approximately 123,190,000 kg CO2e for Scope 1 and about 30,537,000 kg CO2e for Scope 2 emissions. The company has set ambitious climate commitments, aiming for a 50% reduction in Scope 1 and Scope 2 emissions by 2028, compared to 2017 levels. This target was accelerated from an original goal of 2030. Otsuka's broader climate strategy includes a long-term vision to achieve net-zero emissions across all scopes by 2050. This commitment is part of their integrated energy service structure aimed at minimising the total environmental impact of their business activities. The company’s emissions data is sourced from Otsuka Holdings Co., Ltd., reflecting a corporate family relationship. Overall, Otsuka Pharmaceutical is actively working towards significant emissions reductions while enhancing its sustainability practices in line with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 101,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 159,000,000 | - | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 866,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Otsuka Pharmaceutical is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
